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complete pathologic response rate of 9.5% , and 7-year disease-free and 
overall-survival rates of 77% and 79% respectively[11, 12]. 
In general, it is recommended that patients with locally-advanced 
thymic tumors that initially appear inoperable undergo induction che-
motherapy with reassessment for potential surgical resection following 
chemotherapy. A prospective study of a multimodality management 
strategy in thymic tumors found that, compared to historical controls, 
chemotherapy and radiation following surgery appeared to improve 
outcomes for medium risk and high risk thymic tumors[13]. Medium 
risk thymic tumors were deﬁned as stage I and II cortical thymomas/
thymic carcinomas or stage II mixed thymoma, and high risk tumors 
were deﬁned as stage III and IV cortical thymomas/thymics carcinoma 
and stage III mixed thymomas. 
Patients with locally advanced thymic tumors who remain unresectable 
following induction chemotherapy may still be approached with cura-
tive intent via aggressive thoracic radiation. In a phase II Intergroup 
study evaluating 54Gy of radiation following two to four cycles of 
induction PAC (with additional chemotherapy administration following 
radiation), the 5-year failure-free survival was 54% while the median 
time to treatment failure was 93 months[14]. 
Thymic carcinomas appear histologically malignant and follow a more 
aggressive clinical course than thymomas. They display a greater ten-
dency for hematogenous metastasis and carry a worse prognosis. Given 
the rarity of this histologic subtype, prospective phase II studies of 
chemotherapy in only thymic carcinomas are rare. Nonetheless, it does 
appear that while thymic carcinomas are less responsive to chemothera-
py than thymomas, responses nonethless can and do occur[1, 15, 16].
While thymomas and thymic carcinomas can respond to chemotherapy, 
it is critical to remember that chemotherapy is not a cure for widely 
metastatic disease. Thymomas in particular can exhibit an indolent 
course with patients remaining asymptomatic for extended periods 
of time. Therefore, the judicious use of watchful waiting interspersed 
with intermittent, appropriately-timed chemotherapy can optimize the 
survival, symptom palliation, and quality of life for these patients.
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Image guided radiotherapy (IGRT): physicist’s perspective
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There is convincing clinical evidence that image guided radiotherapy 
can substantially increase the therapeutic ratio for a number of dif-
ferent cancer sites. Image guided radiotherapy is a fast-growing and 
technically complex ﬁeld, with many available commercial options to 
improve beam-target alignment. There is also substantial research and 
development into improved image guided technologies. The clinical 
rationale, current available solutions and future prospects of image 
guided therapy will be discussed. 
Educational objectives:
(1) Understand the clinical rationale for improved target accuracy in 
radiotherapy
(2) Describe several available technologies that perform image-guided 
radiotherapy
(3) Understand future developments in image guided radiotherapy
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Introduction: Stereotactic body radiotherapy (SBRT) is a new tech-
nique, introduced in the late 1990s. SBRT is a method of using single 
10-20Gy of high dose and hypofractionated radiotherapy using three-
dimensional conformal technique. Several respiratory regulation meth-
ods have been developed. Recently, many papers have been published 
on its clinical results, in early-stage lung cancer, liver cancer and other 
extracranical tumors. The purpose of this presentation is to evaluate 
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our clinical results and introduce the current status of stereotactic body 
radiotherapy (SBRT) for lung cancer.
Materials and Methods: More than 200 patients have been treated 
with SBRT. Forty-ﬁve patients who were treated between September 
1998 and July 2003 were evaluated. Thirty-one patients had Stage IA 
lung cancer, and the other 14 had Stage IB lung cancer whose tumor 
size was less than 4 cm in diameter. Three-dimensional treatment plan-
ning using 6 to 10 non-coplanar beams was performed to maintain the 
target dose homogeneity, and to decrease the irradiated lung volume 
>20 Gy. All patients were irradiated using a stereotactic body frame and 
received 4 times 12 Gy single high dose radiation at the isocenter over 
a period of 5-13 (median=12) days.
Results: Seven tumors (16%) disappeared completely after treatment 
(CR). Thirty-eight tumors (84%) decreased in size by 30% or more 
(PR) after treatment. Therefore, all tumors showed local response. 
During the follow-up of 5-63 (median=23) months, no pulmonary 
complications greater than an NCI-CTC criteria of grade 3 were noted. 
No other serious complications have not been encountered. All tumors 
except one were locally controlled without apparent evidence of local 
failure during the follow-up period. However, regional nodal recurrenc-
es and distant metastases were in three and four of T1 patients, zero and 
four of T2 patients respectively.
Discussion: The key issues for SBRT are ﬁxing apparatus, respira-
tory regulation, treatment planning and veriﬁcation. A few types of 
stereotactic body frames are available. For regulation of respiratory 
movement, abdominal wall compression, breath-holding, respiratory 
gating and tumor chasing methods were used. For irradiation technique, 
6 to 10 non-coplanar beams or multiple arc beams were adopted. Daily 
veriﬁcation is mandatory for SBRT. Portal ﬁlms, EPID and CT on rails 
were used. Frequently used radiation regimens were 48 to 60 Gy in 3 
to 5 fractions. Single dose radiosurgery technique is still pursued in a 
few institutes. The local control rates were almost always above 90 % 
for lung cancer, with few complications. Long term follow-up results 
have also been reported. Several unanswered questions and currently 
ongoing protocols will be also reviewed. The patient accrual for RTOG 
0236, 60 Gy in 3 fractions was complete, and the operable patient ac-
crual for JCOG 0403, 48 Gy in 4 fractions were also ﬁnished. The other 
multi-institutional studies are underway. 
Conclusions: SBRT seems to be a promising method especially for the 
treatment of early stage lung cancer. 
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Improper knowledge of the patient’s anatomy and position during the 
course of therapy has always been a major source of concern in radia-
tion therapy potentially compromising the clinical results by insuf-
ﬁcient dose coverage of the target volume and/or overdose of normal 
tissues. The management of target localization emanates in the concept 
of treatment margins to cope with the uncertainty of the true location 
of the target volume during irradiation (gross target volume or GTV; 
clinical target volume or CTV; set-up margin or SM; internal margin or 
IM; planning target volume or PTV; and planning risk volume or PRV). 
Concerning these so-called set-up uncertainties, it is generally accepted 
that 2 classes can be identiﬁed, systematic and random. Systematic 
errors exist because the imaging performed for treatment planning is 
typically a snapshot and the target position determined at that instant 
of time may differ from the average target position at treatment time, 
or if a certain procedure introduces an error that is repeated systemati-
cally in time. The random error is the day-to-day deviation from the 
average target position introduced with internal organ motion and the 
repeated treatment set-up that occurs in fractionated radiation therapy. 
The systematic error is generally considered more important, because 
if uncorrected it would propagate throughout the treatment course and 
lead to deleterious effect on local control. On the other hand day-to-
day variations may be substantial requiring safety margins that limit 
the maximum dose administered to the tumour volume due to possible 
toxicity to surrounding healthy tissue. With the introduction of image-
guided radiation therapy (IGRT) clinical conﬁdence has grown and the 
opportunity is given to examine whether the traditional fractionated 
radiation therapy at 2 Gy per fraction is still the optimum strategy. This, 
in turn, introduces treatment schedules using less fractions (so-called 
hypo-fractionation), and the day-to-day variation in target localization 
may no longer be statistically random. And ﬁnally, motion management 
becomes an issue as tumour motion interacts with dose delivery caus-
ing a dose spread along the path of motion in some delivery techniques.
With the improved imaging modalities to deﬁne and delineate tumour 
volumes, identifying both morphologic as well as functional and 
biologic information, and the introduction of treatment modalities that 
allow for shaped dose distributions (e.g. intensity modulated radiation 
therapy or IMRT, stereotactic body radiotherapy or SBRT, and charged 
particle beams), the radiotherapy community is now capable to create 
dose distributions that match the tumour volume tightly. Conformal 
radiation therapy (CRT) aims at shaping the dose distribution to the de-
lineated target volume, whereas conformal avoidance aims at avoiding 
critical structures. These advancements have been driven by the dual 
goals of maximizing radiation dose to tumour volume whilst minimiz-
ing dose to surrounding healthy tissue. It goes without saying that ac-
curate knowledge of the patient’s anatomy during the radiation process 
is of utmost importance and in fact it can be argued that these novel 
technologies such as IMRT and shaped beam radiosurgery are useless 
without proper image-guidance.
The concept of image-guidance as such is not new in radiotherapy. 
Aspects of image guidance have always existed, even with the ﬁrst 
use of x-rays for cancer therapy, probably using the same radiation 
source for both imaging and treatment. The concept of IGRT however, 
has been introduced as to deﬁne the accomplishment of tumour and 
soft tissue imaging in real-time or near real-time for correction of both 
systematic and random errors on a daily basis. It was born out of the 
need for accurate target localization required for IMRT and SBRT, 
and allowing delivery of boost doses to sub-volumes identiﬁed with 
functional and biological imaging. IGRT will be mandatory to exploit 
the possible clinical beneﬁts of these new treatment procedures. As the 
capabilities of IGRT improve, it will provide the tools to better under-
stand treatment uncertainties and allow a re-examination of the present 
practice regarding treatment margins. Conceptually, IGRT refers to 
in-room image-guidance just before or during treatment and is based 
on the assumption that the tumour volume has been deﬁned adequately. 
The imaging modalities applied for tumour identiﬁcation and delinea-
tion, although they also help to ìguide the treatmentî, are not part of the 
IGRT concept in its current deﬁnition.
For simplicity, an ideal IGRT system should have 3 essential elements: 
(a) 3D and if possible motion (4D) assessment of the target volume 
(preferably 3D volumetric information of soft tissue including tumour 
volume), (b) efﬁcient comparison of the image data with reference data, 
